CLINICAL_TRIALS
trial_result
· 2021-01-12
Clinical Trial Update: A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD [Phase 2]
Summary
Phase 2 dose-ranging study of OPT-302 with ranibizumab in neovascular age-related macular degeneration completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Opthea Limited | Conditions: Neovascular Age-related Macular Degeneration | Phase 2 | Status: COMPLETED